PEOPLE

Priti Lal, MD

Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
University of Pennsylvania Perelman School of Medicine

Contact InformationDepartment of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
6 Founders Pavilion
3400 Spruce Street
Philadelphia, PA 19104-4283
Office: 2156626505

Email: priti.lal@uphs.upenn.edu

Specialty Division

Anatomic Pathology

Research Expertise

Application of high through-put technology to gain insights into the biology of human cancers, with special interest in GU cancers.

Clinical Expertise

GU Pathology. Cardiovascular and renal transplantation pathology.

Education

B.S. (Genetics), Delhi University, Delhi, India, 1984
MD Maulana Azad Medical College, Delhi, India, 1990

Specialty Certification

American Board of Pathology, Anatomic Pathology, 2010

Postgraduate Training

Fogarty Fellow, National Institutes of Health, Bethesda, MD, 1993-1995
Fellow, Molecular Biology, National Institutes of Health, Bethesda, MD, 1993-1995
Resident, Pathology, UMDNJ-New Jersey Medical School, Newark NJ, 1996-2000
Visiting Fellow, GI and Liver Pathology, Armed Forces Institute of Pathology, Washington, DC, 1999-1999
Fellow, Oncologic Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 2000-2001
Fellow, Diagnostic Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 2001-2002
Fellow, Research, Memorial Sloan Kettering Cancer Center, New York, NY, 2002-2004

Awards and Honors

Fogarty International Fellowship, NIA, NIH, 1993-1995
Lucien J. Rubinstein Award" for the best Neuropath-oncology paper at the 2010 AANP meeting in Philadelphia, 2010
Nominated for Young investigator award at Cardiovascular society, USCAP 2012.
Platform Presentation. Senior author paper.
Mentored Resident, 2012
Awarded "Poster of Distinction" American Transplant Congress. Senior Author paper. Mentored Resident, 2012
Nominated for the Training and Education commitee for Solid tumors. Association for Molecular Pathologists, 2012
Nominated for Kevin E. Salhany award and the James Wheeler Award, for excellence in clinical teaching and education, 2012
Nominated for Preclinical Teaching Award, Perelman School of Medicine by class of 2017, 2014

Memberships and Professional Organizations

Pennsylvania Association of Pathologists, 2008 - Present
Association for Molecular Pathology, 2010 - 2011
American Society for Clinical Pathology, 2010 - 2011
United States and Canadian Academy of Pathologists, 2010 - 2011
College of American Pathologists, 2010 - Present
ISUP, 2015 - Present
AACR, 2015 - Present

Web Links


Selected Publications

Racial Differences in the Distribution of Prostate Tumor Biomarkers and Treatment Failure: The SCORE Study

Priti Lal, Kosj Yamoah, Amy Ziober, Amy Walker, Wenting Zhou, Elaine Spangler, Charnita Zeigler-Johnson, Michael Feldman, Timothy R. Rebbeck., Clinical Cancer Research, 2015

A novel biomarker signature which may predict aggressive disease in African-American men with prostate cancer.

Kosj Yamoah, Michael Hiroshi Johnson, Voleak Choeurng, Kasra Yousefi, Zaid Haddad, Robert Benjamin Den, Priti Lal, Michael D Feldman, Adam Dicker, Eric A. Klein, Elai Davicioni, Timothy R. Rebbeck, Edward M. Schaeffer, Journal of Clinical oncology, 2015

African-American race is a predictor of seminal vesicle invasion following radical prostatectomy.

Kosj Yamoah, M.D., Ph.D.; Amy Walker, M.S.; Elaine Spangler, M.S.; Charnita M Zeigler-Johnson, M.D., Ph.D.; Bruce Malkowicz, M.D.; David I Lee, M.D.; Adam P Dicker, M.D., Ph.D.; Priti Lal, M.D., Clinical Genitorurinary Cancer, 2014

Chapter 39: Prostate. Diagnostic molecular pathology.

Priti Lal, MD, Diagnostic Molecular pathology, 2nd edition, 2015

Phase II Trial of the CDK 4/6 Inhibitor Palbociclib in Patients with Retinoblastoma Protein Expressing Germ Cell Tumors

David J. Vaughn, MD,Wei-Ting Hwang, PhD,Priti Lal, MD,Mark Rosen, MD Maryann Gallagher, Peter J. O’Dwyer, MD, Cancer, 2014

Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC).

Stephen Michael Keefe, Daniel Heitjan, Meliessa Hennessey, Janelle Robinson, Kristine Mykulowicz, Amy Marshall, Orvar Gunnarsson, Ronac Mamtani, David J. Vaughn, Jean H. Hoffman-Censits, Katherine L. Nathanson, Priti Lal, Daniel A. Pryma, Scott Eliasof, Edward Graeme Garmey, Roger B. Cohen, Naomi B. Haas;, ASCO, 2014

Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity.

Mathew LK, Lee SS, Skuli N, Rao S, Keith B, Nathanson KL, Lal P, Simon MC, Cancer Discov 4(1): 53-60, 2014

Applications of OCT 4 in Diagnostic immunohistochemistry

Priti Lal, MD, Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition, 2014

Application of GATA 3 in diagnostic immunohistochemistry

Priti Lal, MD, Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition, 2014

Application of SALL4 in diagnostic immunohistochemistry

Priti Lal, MD, Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition, 2014